Is Supriya Lifesci. overvalued or undervalued?

As of 30 June 2025, the valuation grade for Supriya Lifesci. has moved from expensive to very expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 30.40, an EV to EBITDA ratio of 21.61, and a PEG ratio of 0.53. In comparison to its peers, Sun Pharma. has a PE ratio of 35.22 and an EV to EBITDA of 24.89, while Cipla stands at a PE of 23.06 and an EV to EBITDA of 15.98, indicating that Supriya Lifesci. is trading at a premium relative to some competitors.
Despite a strong one-year stock return of 83.84% compared to the Sensex's 5.79%, the high valuation metrics suggest that the stock may be priced for perfection. The company's high ROCE of 25.02% and ROE of 20.75% reflect operational efficiency, but these figures do not justify the current valuation levels when compared to industry standards.